E-ISSN 2602-3164
EJMI. 2024; 8(2): 137-143 | DOI: 10.14744/ejmi.2024.49044

Correlation of HALP Score and Menopause Status with Treatment Response in Hormone Receptor-Positive Breast Cancer Patients Receiving Neoadjuvant Chemotherapy

Demet Isik Bayraktar1, Recep Turkel2, Murat Alan2, Guzin Demirag2, Leman Tomak3, Engin Yola4
1Department of Medical Oncology, Sabuncuoglu Serefeddin Training and Research Hospital, Amasya University, Amasya, Türkiye, 2Department of Medical Oncology, Ondokuz Mayıs University, Faculty of Medicine, Samsun, Türkiye, 3Department of Biostatistics and Medical Informatics, Ondokuz Mayis University, Faculty of Medicine, Samsun, Türkiye, 4Department of Internal Medicine, Ondokuz Mayıs University, Faculty of Medicine, Samsun, Türkiye

Objectives: We aimed to investigate the relationship of neoadjuvant therapy with HALP score, menopausal status and pathological response in patients with luminal A and luminal B breast cancer. Methods: In this retrospective study, the files of patients who applied to Ondokuz Mayıs University Medical Oncology department between January 2016 and January 2023 were scanned and a total of 150 patients, 60 premenopausal and 90 postmenopausal, who received neoadjuvant chemotherapy were included. Results: The median age of premenopausal patients was 40.67±6.35 (min 25-max 50), and postmenopausal patients was 57.67±7.48 (min 43-max 78). There was no relationship between overall survival and menopausal status (p=0.33). HALP score was significant only in postmenopausal patients (p=0.008). There was a significant association with com plete pathological response (Miller&Payne 5) and PFS in the entire population (p=0.003). HALP score was lower in patients with PR level below 50% (p=0.039). There was no statistical significant between Ki67 and cerbB2, menopausal status and HALP score (p=0.106, p=0.064, respectively). Conclusion: As a result, we did not detect the relationship between HALP score and pathological response in Luminal A and B patients receiving neoadjuvant therapy. Keywords: Postmenopause, premenopause, HALP Score, neoadjuvan, breast cancer


Cite This Article

Isik Bayraktar D, Turkel R, Alan M, Demirag G, Tomak L, Yola E. Correlation of HALP Score and Menopause Status with Treatment Response in Hormone Receptor-Positive Breast Cancer Patients Receiving Neoadjuvant Chemotherapy. EJMI. 2024; 8(2): 137-143

Corresponding Author: Demet Isik Bayraktar

Full Text PDF PDF Download
EJMI & EJMI